Angiogenesis inhibitors and the need for anti-angiogenic therapeutics
Dass, Crispin R and Tran, T. M. N and Choong, Peter F. M (2007) Angiogenesis inhibitors and the need for anti-angiogenic therapeutics. Journal of Dental Research, 86 (10). pp. 927-936. ISSN 0022-0345Full text for this resource is not available from the Research Repository.
Angiogenesis is the formation of new blood vessels from pre-existing vessels to form capillary networks, which, among other diseases, such as diabetic retinopathy and macular degeneration, is particularly important for tumor growth and metastasis. Thus, depriving a tumor of its vascular supply by means of anti-angiogenic agents has been of great interest since its proposal in the 1970s. This review looks at the common angiogenic inhibitors (angiostatin, endostatin, maspin, pigment epithelium-derived factor, bevacizumab and other monoclonal antibodies, and zoledronic acid) and their current status in clinical trials.
|Uncontrolled Keywords:||ResPubID18883, angiogenesis, therapy, blood vessel, cancer, vasculature|
|Subjects:||FOR Classification > 1102 Cardiovascular Medicine and Haematology
Faculty/School/Research Centre/Department > School of Biomedical and Health Sciences
|Date Deposited:||04 May 2012 04:12|
|Last Modified:||03 Feb 2015 00:20|
|ePrint Statistics:||View download statistics for this item|
|Citations in Scopus:||22 - View on Scopus|
Repository staff only